In a Society of Healthcare Epidemiology of American (SHEA) podcast, Dr. Megan Jeffres, PharmD, BCIDP, discusses why intravenous (IV) to oral (PO) conversion has immense potential to benefit patients by preventing unnecessary intravenous therapy associated with risks such as prolonged length of stay, line-associated infections, and excess cost and inconvenience.
